Login / Signup

ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.

Rafał NiemiecIrmina MorawskaMaria StecWiktoria KuczmikAndrzej Szymon SwinarewArkadiusz StanulaKatarzyna Mizia-Stec
Published in: International journal of environmental research and public health (2022)
Our current positive experience in ARNI therapy is limited to extremely severe patients with HFrEF. Regardless of the more advanced HF and HF comorbidities, the patients treated with ARNI presented similar mortality and rehospitalizations as the patients treated by standard therapy.
Keyphrases
  • acute heart failure
  • type diabetes
  • heart failure
  • stem cells
  • cardiovascular disease
  • atrial fibrillation